Rockwell Medical (RMTI)
NASDAQ:RMTI
Want to see RMTI full AI Analyst Report?
RMTI Stock Chart & Stats
$0.91
-$0.08(-3.59%)
At close: 4:00 PM EST
$0.91
-$0.08(-3.59%)
Day’s Range― - ―
52-Week Range$0.64 - $2.10
Previous CloseN/A
Volume98.98K
Average Volume (3M)306.75K
Market Cap
$26.34M
Enterprise Value$34.13M
Total Cash (Recent Filing)$23.89M
Total Debt (Recent Filing)$14.39M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 17, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding39,470,300
10 Day Avg. Volume404,500
30 Day Avg. Volume306,746
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.43
P/FCF Ratio-24.97
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-13.16
Forecast
1Y Price Target
$3.00Price Target Upside229.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$72.47M
Bulls Say, Bears Say
Bulls Say
Diversified, Recurring Customer BaseServing ~300 customers and 1,400 facilities across 30+ countries creates recurring demand tied to dialysis treatment volumes. This geographic and customer breadth reduces single-account dependency, supports predictable consumption-based revenue, and enhances resilience versus localized shocks over months.
Operational Capacity And Margin ExpansionAutomation that increases output ~50% and lowers per-bottle costs provides structural operating leverage. Estimated incremental gross profit (~$3M, with ~$1.5M in 2026) supports durable gross-margin expansion and scalable production economics, improving long-term margin sustainability if execution holds.
Improved Balance Sheet LeverageMaterially lower leverage (debt-to-equity ~0.33–0.42) and stronger equity reduce solvency risk and increase financial flexibility. A healthier capital structure supports investment in capacity, tolerates temporary operating setbacks, and lowers refinancing risk over the next several months.
Bears Say
Inconsistent Profitability And Cash FlowThe company has swung between positive and negative operating and free cash flow, with 2025 returning to losses and TTM deterioration. This uneven cash generation suggests reliance on timing, one-offs, or working-capital moves, raising execution risk and clouding the durability of the current turnaround.
Revenue Volatility Tied To Large CustomersAn 8% YoY revenue drop driven by reduced volume from a major customer highlights sensitivity to large-account behavior. Such concentration-driven swings undermine revenue predictability and can pressure pricing and utilization, complicating planning and margin realization over the medium term.
Nasdaq Bid-price Non-compliance And Reverse-split RiskA Nasdaq deficiency notice and proposed reverse split introduce structural governance and liquidity risks. Listing pressure can distract management, deter institutional interest, and narrow trading liquidity; a reverse split may also be perceived negatively by counterparties and investors, affecting medium-term market access.
Rockwell Med News
RMTI FAQ
What was Rockwell Medical’s price range in the past 12 months?
Rockwell Medical lowest stock price was $0.64 and its highest was $2.10 in the past 12 months.
What is Rockwell Medical’s market cap?
Rockwell Medical’s market cap is $26.34M.
When is Rockwell Medical’s upcoming earnings report date?
Rockwell Medical’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were Rockwell Medical’s earnings last quarter?
Rockwell Medical released its earnings results on May 07, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.015.
Is Rockwell Medical overvalued?
According to Wall Street analysts Rockwell Medical’s price is currently Undervalued.
Does Rockwell Medical pay dividends?
Rockwell Medical does not currently pay dividends.
What is Rockwell Medical’s EPS estimate?
Rockwell Medical’s EPS estimate is -0.03.
How many shares outstanding does Rockwell Medical have?
Rockwell Medical has 39,470,300 shares outstanding.
What happened to Rockwell Medical’s price movement after its last earnings report?
Rockwell Medical reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -3.58%.
Which hedge fund is a major shareholder of Rockwell Medical?
Currently, no hedge funds are holding shares in RMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rockwell Medical
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
RMTI Company Deck
RMTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized operational improvements (automation increasing capacity ~50%), margin expansion (gross margin +2 percentage points YoY), renewed contracts and an active customer pipeline, accompanied by concrete 2026 guidance (net sales $70–75M, gross margin 18–22%, adjusted EBITDA $1–2M, positive operating cash flow) and a clear plan to achieve positive net income in H2 2026. The primary negatives were a modest YoY revenue decline (-8% in Q1) driven by lower volumes from a prior large customer, a small Q1 net loss ($1.6M) and a slight decrease in cash due to seasonal items and a $0.5M acquisition payment. Overall, the positives around operational capacity increases, margin improvement, diversified customer base, and constructive guidance materially outweigh the modest near-term headwinds.View all RMTI earnings summariesRMTI Stock 12 Month Forecast
Average Price Target
$3.00
▲(229.67% Upside)
Technical Analysis
Ownership Overview
2.60% Insiders
3.82% Mutual Funds
1.24% Other Institutional Investors
89.20% Public Companies and
Individual Investors